Chemotherapy and Targeted Therapy

Rescuing Innovation: How the Children’s Tumor Foundation is Unlocking Shelved Rare Disease Therapies rescuing-innovation-how-the-childrens-tumor-foundation-is-unlocking-shelved-rare-disease-therapies

Rescuing Innovation: How the Children’s Tumor Foundation is Unlocking Shelved Rare Disease Therapies

Muslim July 13, 2026

In the high-stakes world of pharmaceutical development, the journey from laboratory bench to patient bedside is often...

The Hybrid Revolution: Remepy’s AI-Driven Approach to Redefining Chronic Disease Management the-hybrid-revolution-remepys-ai-driven-approach-to-redefining-chronic-disease-management

The Hybrid Revolution: Remepy’s AI-Driven Approach to Redefining Chronic Disease Management

Muslim July 12, 2026

The long-held promise of the digital health revolution—that smartphones would one day act as medical instruments as...

The Strategic Pivot: How U.S. Biotech is Redefining Innovation in an Era of Global Competition the-strategic-pivot-how-u-s-biotech-is-redefining-innovation-in-an-era-of-global-competition-1

The Strategic Pivot: How U.S. Biotech is Redefining Innovation in an Era of Global Competition

Basiran July 12, 2026

The American biotechnology sector, long considered the undisputed global leader in pharmaceutical innovation, finds itself at a...

The New Frontier: Boehringer Ingelheim Targets MASH with Survodutide the-new-frontier-boehringer-ingelheim-targets-mash-with-survodutide

The New Frontier: Boehringer Ingelheim Targets MASH with Survodutide

Pevita Pearce July 12, 2026

For decades, the medical community viewed metabolic dysfunction-associated steatohepatitis (MASH)—formerly known as NASH—as a clinical "graveyard." Despite...

From Anesthetic Roots to Psychiatric Blockbuster: The Evolution of Spravato and the Pursuit of Depression Remission from-anesthetic-roots-to-psychiatric-blockbuster-the-evolution-of-spravato-and-the-pursuit-of-depression-remission

From Anesthetic Roots to Psychiatric Blockbuster: The Evolution of Spravato and the Pursuit of Depression Remission

Layla Zulfa July 12, 2026

Sixty years after Calvin Stevens first synthesized ketamine at Parke-Davis in a pursuit of safer anesthesia, the...

The Future of Precision Oncology: Merck’s Calderasib and the Pivot to Combinability the-future-of-precision-oncology-mercks-calderasib-and-the-pivot-to-combinability

The Future of Precision Oncology: Merck’s Calderasib and the Pivot to Combinability

Asro July 11, 2026

For decades, the KRAS gene—a critical regulator of cellular growth—was considered the "holy grail" of oncology and...

Scaling the Future: Maja Herold Pedersen on the Digital Transformation of FUJIFILM Biotechnologies scaling-the-future-maja-herold-pedersen-on-the-digital-transformation-of-fujifilm-biotechnologies

Scaling the Future: Maja Herold Pedersen on the Digital Transformation of FUJIFILM Biotechnologies

Pevita Pearce July 11, 2026

In the high-stakes world of biopharmaceutical manufacturing, the transition from clinical-stage promise to commercial-scale reality is often...

Biotech Weekly Roundup: ARPA-H’s Genetic Revolution and Strategic Industry Shifts biotech-weekly-roundup-arpa-hs-genetic-revolution-and-strategic-industry-shifts

Biotech Weekly Roundup: ARPA-H’s Genetic Revolution and Strategic Industry Shifts

Asep Darmawan July 10, 2026

The biotechnology sector has seen a flurry of activity this week, characterized by bold government-led initiatives in...

Scaling Solubility: AustinPx and Thermo Fisher Scientific Forge Strategic Alliance to Revolutionize Amorphous Solid Dispersions scaling-solubility-austinpx-and-thermo-fisher-scientific-forge-strategic-alliance-to-revolutionize-amorphous-solid-dispersions

Scaling Solubility: AustinPx and Thermo Fisher Scientific Forge Strategic Alliance to Revolutionize Amorphous Solid Dispersions

Laily UPN July 10, 2026

In a move set to redefine the landscape of small-molecule drug development, AustinPx, a Texas-based contract development...

Clinical Setback: Eplontersen Fails Key Phase 3 Trial, Reshaping the ATTR-CM Competitive Landscape clinical-setback-eplontersen-fails-key-phase-3-trial-reshaping-the-attr-cm-competitive-landscape

Clinical Setback: Eplontersen Fails Key Phase 3 Trial, Reshaping the ATTR-CM Competitive Landscape

Iffa Jayyana July 9, 2026

By [Author Name/Staff Reporter] Published July 9, 2026 In a stunning development that has sent shockwaves through...

Chemotherapy and Targeted Therapy

Rescuing Innovation: How the Children’s Tumor Foundation is Unlocking Shelved Rare Disease Therapies

The Hybrid Revolution: Remepy’s AI-Driven Approach to Redefining Chronic Disease Management

The Strategic Pivot: How U.S. Biotech is Redefining Innovation in an Era of Global Competition

The New Frontier: Boehringer Ingelheim Targets MASH with Survodutide

From Anesthetic Roots to Psychiatric Blockbuster: The Evolution of Spravato and the Pursuit of Depression Remission

The Future of Precision Oncology: Merck’s Calderasib and the Pivot to Combinability

Scaling the Future: Maja Herold Pedersen on the Digital Transformation of FUJIFILM Biotechnologies

Biotech Weekly Roundup: ARPA-H’s Genetic Revolution and Strategic Industry Shifts

Scaling Solubility: AustinPx and Thermo Fisher Scientific Forge Strategic Alliance to Revolutionize Amorphous Solid Dispersions

Clinical Setback: Eplontersen Fails Key Phase 3 Trial, Reshaping the ATTR-CM Competitive Landscape

You may have missed

Mastering the Gravity-Defying Flow: The Art of the Ashtanga Jump-Back

Cultivating Prosperity: The BRIDGES Engine and the Future of Rural Agriculture

A Lifesaving Breakthrough for BRCA Carriers: Cambridge Study Confirms Bilateral Salpingo-Oophorectomy Significantly Reduces Early Death Risk

The Pan-Viral Frontier: Can Cocrystal Pharma Rewrite the Rules of Antiviral Development?